A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Nov 6, 2012

Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting

Read more about Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
Nov 1, 2012

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Acquisition of Own Shares
Oct 30, 2012

Astellas Pharma Announces Launch of Quattrovac® for Subcutaneous Injection Syringe, Adsorbed Purified Pertussis Diptheria Tetanus Inactivated Poliomyelitis (Sabin strain) Combined Vaccine

Read more about Astellas Pharma Announces Launch of Quattrovac® for Subcutaneous Injection Syringe, Adsorbed Purified Pertussis Diptheria Tetanus Inactivated Poliomyelitis (Sabin strain) Combined Vaccine
Oct 22, 2012

Astellas Enters Collaborative New Drug Discovery Research with AIST for Neglected Tropical Diseases Caused by Protozoan Parasites

- Through Drug Design Using Fragment Evolution -

Read more about Astellas Enters Collaborative New Drug Discovery Research with AIST for Neglected Tropical Diseases Caused by Protozoan Parasites
Oct 22, 2012

Astellas Launches Gonax® (Degarelix Acetate) for Subcutaneous Injection in Japan for Treating Prostate Cancer

Read more about Astellas Launches Gonax® (Degarelix Acetate) for Subcutaneous Injection in Japan for Treating Prostate Cancer
Oct 22, 2012

MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies

Read more about MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies
Oct 19, 2012

MIRABEGRON RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS

Read more about MIRABEGRON RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS
Oct 17, 2012

Astellas Pharma Inc.: Donation of Six Wheelchair Vans by Employee-Run Social Contribution Fund “Flying Star Fund”

Read more about Astellas Pharma Inc.: Donation of Six Wheelchair Vans by Employee-Run Social Contribution Fund “Flying Star Fund”
Oct 3, 2012

Astellas Announces Poster Presentation of SGLT2 Inhibitor (Ipragliflozin) Detailing Efficacy and Safety in Combination with Other Hypoglycemic Agents in Patients with Type 2 Diabetes at the European Association for the Study of Diabetes Meeting

Read more about Astellas Announces Poster Presentation of SGLT2 Inhibitor (Ipragliflozin) Detailing Efficacy and Safety in Combination with Other Hypoglycemic Agents in Patients with Type 2 Diabetes at the European Association for the Study of Diabetes Meeting
Oct 1, 2012

AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer First Patient Enrolled in TAURUS Patient Preference Study

CAMBRIDGE, Mass. and TOKYO, Japan, October 1, 2012 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial (TIvozanib Versus...

Read more about AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer First Patient Enrolled in TAURUS Patient Preference Study

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts